TL;DR: In preclinical and early-phase human research, CJC-1295 (a long-acting GHRH analog) and ipamorelin (a selective ghrelin-receptor secretagogue) act on two separate pituitary pathways. Studied together, they raise growth hormone more than either alone, with ipamorelin favored for not disturbing cortisol or prolactin. All data is research-context only.
Why these two peptides are studied together
Growth hormone (GH) release from the pituitary is governed by two main stimulatory inputs. Growth hormone-releasing hormone (GHRH) binds the GHRH receptor on somatotroph cells and drives cAMP-dependent GH synthesis and release. Ghrelin and synthetic ghrelin-mimetics (the GHRP class) bind a separate receptor, GHS-R1a, amplifying the release signal and blunting somatostatin, GH’s natural “brake.”
CJC-1295 is a synthetic GHRH analog. Ipamorelin is a pentapeptide that agonizes GHS-R1a. Because they engage distinct G-protein-coupled receptors, researchers have long paired a GHRH analog with a GHRP-type compound to study whether the two produce a combined GH response larger than the sum of the parts. That two-pathway rationale is the reason the CJC-1295 + ipamorelin blend became the archetypal GH-secretagogue pairing in the literature and in research supply.
Two important clarifications up front. First, “CJC-1295” in most modern blends refers to the version without DAC (also called modified GRF 1-29), which has a short half-life of roughly 30 minutes and preserves pulsatile GH release. The original DAC (drug affinity complex) version binds albumin and persists for days. Second, none of this is a therapy: these are laboratory reference compounds, and the discussion below describes research findings, not human protocols.
The mechanism, side by side
| Feature | CJC-1295 (mod GRF 1-29) | Ipamorelin |
|---|---|---|
| Class | GHRH analog | Selective ghrelin-receptor (GHS-R1a) agonist / GHRP |
| Receptor | GHRH receptor | GHS-R1a |
| Signaling | cAMP-dependent GH synthesis and release | Ca2+-dependent release; suppresses somatostatin |
| Half-life (no-DAC form) | ~30 minutes | ~2 hours |
| Selectivity note | Raises GH/IGF-1 axis | No significant ACTH, cortisol, or prolactin rise in animal models |
| Role in the blend | Sets up the GH “signal” | Amplifies the release “pulse” |
Log-scale spread: the no-DAC forms clear in minutes to hours, while the DAC version persists for days.
The complementary logic is straightforward on paper: CJC-1295 increases the amount of GH the somatotroph is primed to release, while ipamorelin triggers a stronger, cleaner discharge of that pool. Because their receptors and second-messenger systems differ, co-stimulation has repeatedly been described as synergistic rather than merely additive in cell and human studies of GHRH-plus-GHRP combinations.
Why ipamorelin is favored for selectivity
Ipamorelin was first described by Raun and colleagues in 1998 as “the first selective growth hormone secretagogue.” In their animal work, ipamorelin released GH with a potency comparable to older GHRPs such as GHRP-6 and hexarelin, but with a critical difference: even at doses far above the level needed for GH release, it did not meaningfully raise adrenocorticotropic hormone (ACTH) or cortisol. Earlier GHRPs tended to spill over onto these stress-hormone pathways.
That selectivity is the main reason ipamorelin, rather than GHRP-2 or GHRP-6, is the ghrelin-mimetic most often paired with CJC-1295 in research contexts. The stated research goal is a GH pulse with fewer off-target endocrine effects. It is worth stressing that this selectivity profile comes largely from preclinical and mechanistic studies; large, long-term controlled human trials of ipamorelin for GH optimization are lacking.
What the research shows
The evidence base is a mix of solid early-phase human pharmacology on the individual peptides and much thinner data on the specific fixed blend.
On CJC-1295. Teichman and colleagues (2006) ran randomized, double-blind, placebo-controlled ascending-dose trials of CJC-1295 (the DAC version) in healthy adults. Single injections produced roughly 2- to 10-fold increases in GH lasting several days and 1.5- to 3-fold IGF-1 elevations lasting 9 to 11 days. A companion study by Ionescu and Frohman (2006) showed that GH secretion remained pulsatile during continuous CJC-1295 stimulation rather than flattening into a continuous elevation, a pharmacodynamic point researchers consider favorable. Sackmann-Sala and colleagues (2009) later documented measurable downstream serum-protein changes after a single CJC-1295 injection, confirming genuine GH/IGF-1 axis activation.
On ipamorelin. The primary human-relevant characterization remains the mechanistic selectivity work descending from Raun et al. Ipamorelin is well described at the receptor and animal-physiology level, but published controlled human efficacy trials are limited.
On the combination. The synergy rationale rests on classic GHRH-plus-GHRP pharmacology, exemplified by Bowers and colleagues, who showed decades ago that submaximal GHRP combined with GHRH produced GH responses exceeding either agent alone. Independent, peer-reviewed clinical trials of the specific CJC-1295 + ipamorelin fixed blend, at the doses sold for research, are essentially absent. Reviews such as Sigalos and Pastuszak (2018) note that a general paucity of controlled data still limits firm conclusions about GH secretagogues as a class. In short: the mechanism is well-grounded; the blend-specific clinical evidence is not.
The pre-mixed blend, in research context
Because the two peptides are studied together so consistently, suppliers commonly offer a single vial containing both, typically at a higher CJC-1295 to ipamorelin ratio. A pre-mixed 10 mg CJC-1295 + ipamorelin blend reduces the number of separate reconstitutions a lab needs to perform and keeps the ratio consistent across a study. Researchers who want to vary the ratio independently instead source the two components separately.
Reconstitution volume, concentration per unit, and ratio all affect how a blend is quantified in a research setting. A reconstitution and concentration calculator is useful for converting between total milligrams in a vial, diluent volume, and concentration per unit, purely for laboratory measurement and record-keeping.
Frequently asked questions
What is the difference between CJC-1295 and ipamorelin?
They act on different receptors. CJC-1295 is a GHRH analog that binds the GHRH receptor and drives GH synthesis. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that triggers GH release and suppresses somatostatin. Researchers pair them to engage both pathways at once.
Why are CJC-1295 and ipamorelin combined into one blend?
Because their receptors and signaling systems are distinct, co-stimulation has been described as synergistic rather than additive in GHRH-plus-GHRP studies. A pre-mixed blend keeps the ratio fixed and simplifies handling. It is a research convenience, not evidence of a validated therapeutic combination.
Is “CJC-1295” in a blend the DAC or no-DAC version?
Most modern blends use CJC-1295 without DAC (modified GRF 1-29), which has a roughly 30-minute half-life and preserves pulsatile GH release. The DAC version binds albumin and lasts several days. Product listings and certificates of analysis should specify which form is present.
Why is ipamorelin considered more selective than other GHRPs?
In the 1998 Raun study, ipamorelin released GH without meaningfully raising ACTH, cortisol, or prolactin, even at high doses, whereas older GHRPs such as GHRP-6 and hexarelin tended to elevate those hormones. That cleaner profile is why ipamorelin is the preferred ghrelin-mimetic in this pairing.
Is there human clinical trial evidence for the blend?
The individual peptides have early-phase human pharmacology (notably CJC-1295) and strong mechanistic data (ipamorelin). Independent controlled trials of the specific fixed blend at research doses are essentially absent. The combination’s appeal rests on receptor-level rationale, not on blend-specific clinical outcomes.
Can I use this blend for anti-ageing or muscle growth?
No. These are research-use-only reference materials. PeptiMap does not provide dosing guidance or therapeutic recommendations, and no human use is described or endorsed here. Any interpretation of the research is for educational, laboratory context only.
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797.
- Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. The Journal of Clinical Endocrinology & Metabolism. 1990;70(4):975-982.
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research. 2009;19(6):471-477.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews. 2018;6(1):45-53.
Research use only. This article is an educational reference and does not constitute medical advice, dosing guidance, or a recommendation for human use. The compounds discussed are not approved therapies. Evidence for the specific blend is limited and largely preclinical or early-phase; statements here describe published research, not clinical outcomes.